Impact of infant 13-valent pneumococcal conjugate vaccine on serotypes in adult pneumonia
Updated: Jun 10, 2019
Infant 13-valent pneumococcal conjugate vaccination (PCV13) was introduced to the UK in 2010. Its impact on serotypes implicated in adult non-bacteraemic pneumococcal pneumonia is not known. Beginning in 2008, a 5-year prospective cohort study of adults admitted to hospital with community-acquired pneumonia (CAP) was conducted.
Investigator: Lin Wei Shen
This research was published in the European Respiratory Journal in June 2015: